首页/数据集/The dual HDAC-PI3K inhibitor CUDC-907 displays potent antitumor activity in ovarian cancer

The dual HDAC-PI3K inhibitor CUDC-907 displays potent antitumor activity in ovarian cancer

NIAID Data Ecosystem2026-05-01 收录

卵巢癌治疗

临床前药效评估

数据链接：

https://www.ncbi.nlm.nih.gov/sra/SRP429312 数据链接链接失效反馈

官方服务：

资源简介：

we aimed to measure the efficacy of CUDC-907 in ovarian cancer cells

应用场景：

创建时间：

2024-04-05

卵巢癌治疗

Wnt/β-catenin信号通路抑制

The poor prognosis of ovarian cancer patients mainly results from a lack of early diagnosis approaches and a high rate of relapse. Only a very modest improvement has been made in ovarian cancer patien

NIAID Data Ecosystem100

Complete list of synlet interactions addressed by novel drug combinations.

合成致死药物

卵巢癌治疗

The full list of addressed synlet interactions as well as the respective novel proposed drug combinations are given in the S1 Table. Synlet interactions are sorted in descending order based on the sum

NIAID Data Ecosystem50

Table_2_What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China.docx

卵巢癌治疗

PARP1抑制剂

ObjectiveThis study assessed the real-world application, effectiveness, and safety of olaparib and niraparib as maintenance therapies in patients with platinum-sensitive recurrent ovarian cancer (PSRO

NIAID Data Ecosystem40

Dual inhibition of Src and MEK decreases the growth of human ovarian cancer cells

卵巢癌治疗

激酶抑制剂联合疗法

Treatment of established lines and primary ovarian cancer cultures with Src and MEK inhibitors, saracatinib and selumetinib, respectively, showed target kinase inhibition and synergistic induction of

NIAID Data Ecosystem50

Combination treatment with 17-AAG and CDDP or DTIC.

肿瘤联合用药

临床前药效评估

Combination treatment with 17-AAG and CDDP or DTIC.

Figshare2016-04-06 更新40